JP2012502061A5 - - Google Patents

Download PDF

Info

Publication number
JP2012502061A5
JP2012502061A5 JP2011526247A JP2011526247A JP2012502061A5 JP 2012502061 A5 JP2012502061 A5 JP 2012502061A5 JP 2011526247 A JP2011526247 A JP 2011526247A JP 2011526247 A JP2011526247 A JP 2011526247A JP 2012502061 A5 JP2012502061 A5 JP 2012502061A5
Authority
JP
Japan
Prior art keywords
active ingredient
composition
composition according
hours
zein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011526247A
Other languages
English (en)
Japanese (ja)
Other versions
JP5608653B2 (ja
JP2012502061A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/056103 external-priority patent/WO2010028290A1/en
Publication of JP2012502061A publication Critical patent/JP2012502061A/ja
Publication of JP2012502061A5 publication Critical patent/JP2012502061A5/ja
Application granted granted Critical
Publication of JP5608653B2 publication Critical patent/JP5608653B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2011526247A 2008-09-04 2009-09-04 チュアブルな徐放性製剤 Expired - Fee Related JP5608653B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9436308P 2008-09-04 2008-09-04
US61/094,363 2008-09-04
PCT/US2009/056103 WO2010028290A1 (en) 2008-09-04 2009-09-04 Chewable sustained release formulations

Publications (3)

Publication Number Publication Date
JP2012502061A JP2012502061A (ja) 2012-01-26
JP2012502061A5 true JP2012502061A5 (enExample) 2012-09-20
JP5608653B2 JP5608653B2 (ja) 2014-10-15

Family

ID=41219093

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526247A Expired - Fee Related JP5608653B2 (ja) 2008-09-04 2009-09-04 チュアブルな徐放性製剤

Country Status (8)

Country Link
US (1) US10668012B2 (enExample)
EP (1) EP2331076B1 (enExample)
JP (1) JP5608653B2 (enExample)
CN (1) CN102202654B (enExample)
AU (1) AU2009289464B2 (enExample)
CA (1) CA2736119C (enExample)
ES (1) ES2536736T3 (enExample)
WO (1) WO2010028290A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400578B1 (it) 2010-06-18 2013-06-14 Alpex Pharma Sa Processo per la preparazione di compresse a rilascio controllato.
EP2785333A4 (en) 2011-12-02 2015-04-01 Pegasus Lab Inc AMPHIPATIVE COMPOSITIONS WITH DELAYED RELIEF ON LIPID BASIS
US10722458B2 (en) * 2011-12-02 2020-07-28 Pegasus Laboratories, Inc. Amphipathic lipid-based sustained release compositions
EP2846773A4 (en) 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
CN103686676A (zh) * 2012-08-31 2014-03-26 中兴通讯股份有限公司 设备到设备通信系统的通信方法、装置及系统
US20140080908A1 (en) * 2012-09-19 2014-03-20 Phyto Tech Corp. Compositions and methods for improving or preventing depression-like symptoms
JP6378702B2 (ja) 2013-03-15 2018-08-22 アルジェンタ マニュファクチャリング リミティド チュアブル製剤
JP7418958B2 (ja) 2016-03-17 2024-01-22 チオジェネシス セラピューティクス, インコーポレイテッド システアミンの制御放出のための組成物及びシステアミン感受性障害の全身治療
JP6800596B2 (ja) * 2016-03-29 2020-12-16 小林製薬株式会社 錠剤
WO2018064238A1 (en) * 2016-09-27 2018-04-05 Zolentroff William C Ala and salt formulation
EP3589276B9 (en) * 2017-07-26 2024-01-17 TGX Soft Chew, LLC Starch-free soft chew for veterinary applications
CN109420163B (zh) * 2017-08-23 2022-06-21 中山市力恩普制药有限公司 治疗呼吸道感染的药物组合物及其制备方法和用途
WO2019060634A1 (en) 2017-09-20 2019-03-28 Thiogenesis Therapeutics, Inc. METHODS OF TREATING CYSTEAMINE SENSITIVE DISORDERS
EP3902523A1 (en) * 2018-12-29 2021-11-03 3M Innovative Properties Company Oral articles and methods of use
US20220080019A1 (en) * 2018-12-29 2022-03-17 3M Innovative Properties Company Oral articles and methods of use
CN111744018A (zh) * 2019-03-26 2020-10-09 北京福元医药股份有限公司 一种盐酸氨基葡萄糖药物制剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3567819A (en) * 1969-01-30 1971-03-02 Hoffmann La Roche Cold tablet
US5032406A (en) * 1989-02-21 1991-07-16 Norwich Eaton Pharmaceuticals, Inc. Dual-action tablet
GB8913889D0 (en) 1989-06-16 1989-08-02 May & Baker Ltd New compositions of matter
US5182130A (en) * 1989-11-06 1993-01-26 Opta Food Ingredients, Inc. Method for producing an edible prolamine coating from an aqueous latex
US5077053A (en) * 1990-02-12 1991-12-31 Warner-Lambert Company Zein as a moisture barrier for sugarless edible compositions and method for preparing same
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
DE19630035A1 (de) 1996-07-25 1998-01-29 Asta Medica Ag Tramadol Multiple Unit Formulierungen
JP3877083B2 (ja) * 1996-08-03 2007-02-07 昭和産業株式会社 第4胃以降消化・吸収性反芻動物用飼料製剤並びにそれを含有する反芻動物用飼料
FR2752732B1 (fr) 1996-08-28 1998-11-20 Pf Medicament Forme galenique a liberation prolongee de milnacipran
US5904937A (en) * 1997-10-03 1999-05-18 Fmc Corporation Taste masked pharmaceutical compositions
AU747549B2 (en) 1998-03-23 2002-05-16 General Mills Inc. Encapsulation of components into edible products
US7815937B2 (en) * 1998-10-27 2010-10-19 Biovail Laboratories International Srl Quick dissolve compositions and tablets based thereon
ES2374717T3 (es) * 1999-10-29 2012-02-21 Euro-Celtique S.A. Formulaciones de hidrocodona de liberación controlada.
US6277409B1 (en) * 2000-02-11 2001-08-21 Mcneil-Ppc, Inc. Protective coating for tablet
US20020106408A1 (en) * 2000-12-01 2002-08-08 Johnatan Bacon Prolamin-based sustained-release compositions and delayed-onset compositions
IL151150A0 (en) 2001-01-31 2003-04-10 Roehm Gmbh Multiparticulate drug form comprising at least two differently coated pellet forms
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
US7612112B2 (en) * 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
BR0312206A (pt) 2002-06-27 2005-04-12 Cilag Ag Formulações de pélete esférico
AU2003247876B2 (en) * 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
GB2403407B (en) 2003-07-03 2006-12-13 Michael Hilary Burke Palatable oral anthelmintic composition
WO2005041935A1 (en) * 2003-10-21 2005-05-12 Alpharma, Inc. Pharmaceutical formulations containing quetiapine
US20050089558A1 (en) 2003-10-28 2005-04-28 Alamo Pharmaceuticals, Llc Compositions and methods for the co-formulation and administration of tramadol and propoxyphene
LT2522365T (lt) * 2004-11-24 2017-02-10 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai
JP4050784B2 (ja) 2005-02-03 2008-02-20 株式会社Nrlファーマ マトリックス型腸溶性・徐放性組成物
JP4602949B2 (ja) 2006-08-02 2010-12-22 和光堂株式会社 被覆粒子含有組成物及びその製造方法

Similar Documents

Publication Publication Date Title
JP2012502061A5 (enExample)
US20210113469A1 (en) Sustained release compositions using wax-like materials
CN102202654B (zh) 可咀嚼的缓释制剂
EP0785775B2 (en) Melt-extruded orally administrable opioid formulations
JP6240279B2 (ja) 制御放出ヒドロコドン処方
CN1942174B (zh) 微粒
JP2017031206A (ja) ラコサミドの1日1回投与用製剤
TW200427448A (en) Controlled release preparations comprising tramadol and topiramate
CN103520130B (zh) 孟鲁斯特钠择时控释片及其制备方法
WO2013121233A1 (en) Pharmaceutical formulation having improved stability
CN103520136B (zh) 孟鲁斯特钠脉冲胶囊及其制备方法
KR20090047310A (ko) 덱시부프로펜을 함유하는 다층정제
CN101537005B (zh) 可待因和氯苯那敏复方缓释胶囊
CN101234095B (zh) 一种定时释放制剂及其制备方法
KR20080075113A (ko) 에스시탈로프람 및 부프로피온을 함유하는 안정한 약학적제형
HK1141441B (en) Sustained release pellets comprising wax-like material
JP2006089461A (ja) 覚醒剤原料含有レイアリング顆粒
HK1069110B (en) Melt-extruded orally administrable opioid formulations
HK1069109B (en) Melt-extruded orally administrable opioid formulations